BEGIN:VCALENDAR VERSION:2.0 PRODID:-//ZContent.net//ZapCalLib 1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VEVENT SUMMARY:Glycoscience Tools and Therapeutics LOCATION:Chemistry A101 TZID:America/Denver DTSTART:20260202T160000 UID:2026-04-22-00-52-42@natsci.colostate.edu DTSTAMP:20260422T005242 Description:Abstract:\n\nGlycans regulate many biological processes\, but w eak and transient carbohydrate-protein interactions are difficult to detec t in native settings\, and disease-associated glycosylation changes are of ten hard to exploit. In this seminar\, I will present two complementary ch emical strategies that convert glycan recognition into actionable readouts for discovery and targeting. First\, I will introduce carbohydrate-direct ed labeling probes (CDLPs)\, a modular class of ligand-directed covalent p robes in which a carbohydrate ligand and a bioorthogonal handle flank a tu ned electrophile. Carbohydrate binding positions the electrophile near nuc leophilic residues on carbohydrate-binding proteins (CBPs)\, trapping flee ting interactions as stable covalent adducts for detection and profiling. CDLPs function in purified systems\, live cells\, and native proteomes\, e nabling detection of millimolar-affinity interactions in a ligand- and com petition-dependent manner. A 6′-sialyllactose CDLP selectively labels  CD22 on B cells\, and quantitative chemoproteomics with sialyllactose- a nd lactose-CDLPs maps complementary\, ligand-specific networks while uncov ering proteins without prior carbohydrate annotations. Second\, I will des cribe lectin drug conjugates (LDCs) that leverage cancer-associated incre ases in high mannose N-glycans to deliver toxins selectively to cancer c ells. Moreover\, cells with low high mannose levels can be sensitized by c o-treatment with a type I mannosidase inhibitor. Together\, these approach es demonstrate how chemical tools can both illuminate glycan-binding biolo gy and translate aberrant glycosylation into therapeutic opportunity.\n\n& nbsp\;\n\nSpeaker Bio:\nDr. Mark Farrell completed his undergraduate and d octoral studies in Chemistry at the National University of Ireland\, Galwa y. His PhD studies were supported by Roche and focused on stereoselective methods for glycosidic bond formation under the mentorship of Professor P aul V. Murphy. Following his PhD\, he joined the laboratory of Professor A mos B. Smith III at the University of Pennsylvania as a postdoctoral fello w\, where he developed new Anion Relay Chemistry methods and synthetic app roaches to natural products and HIV-1 entry inhibitors. In 2017\, he join ed the Department of Medicinal Chemistry at the University of Kansas Schoo l of Pharmacy\, where he is now an Associate Professor\, the Director of Graduate Studies\, and Co-Leader of the Drug Discovery\, Delivery\, &\ ; Experimental Therapeutics (D3ET) Program at the University of Kansas Co mprehensive Cancer Center. He also leads the Synthetic Chemical Biology C ore for the NIH-funded Center for Chemical Biology of Infectious Disease (CBID). Dr. Farrell’s research group integrates synthetic chemistry\, gl ycobiology\, and immunology to develop chemical tools that uncover how gl ycan-protein interactions regulate immune pathways and influence cancer pr ogression. His work spans the development of lectin-based probes\, glycan -specific inhibitors\, and chemical strategies to enhance cell-based immu notherapies. 4:00 pm END:VEVENT END:VCALENDAR